Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone A multivariate analysis of over 5000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012 2013

Prognostic indicators of assisted reproductive technology cycles with ultralow antimullerian hormone are identified and assessed by multivariate analysis of over 5,000 autologous cycles from the 2012–2013 Society for Assisted Reproductive Technology Clinic Outcome Reporting System database.

David B. Seifer, M.D., Oded Tal, Ph.D., Ethan Wantman, M.B.A., Pretti Edul, M.A., Valerie L. Baker, M.D.

Volume 105, Issue 2, Pages 385-393


To assess cycle outcomes when antimüllerian hormone (AMH) is ultralow (≤0.16 ng/mL) and to determine which parameters contribute to the probability of cycle cancellation and/or outcome.

Retrospective analysis.

Not applicable.

5,087 (7.3%) fresh and 243 (1.5%) thawed cycles with ultralow AMH values.

Linear and logistic regression, comparison with age-matched cycles with normal AMH concentrations.

Main Outcome Measure(s):
Cancellation rate; number of retrieved oocytes, embryos, transferred embryos, and cryopreserved embryos; clinical pregnancy, live-birth, and multiple birth rates.

The total cancellation rate per cycle start for fresh cycles was 54%. Of these, 38.6% of the cycles were canceled before retrieval, and 3.3% of cycles obtained no oocytes at time of retrieval. Of all retrieval attempts, 50.7% had three oocytes or fewer retrieved, and 25.1% had no embryo transfer. The live-birth rates were 9.5% per cycle start. Cycles with ultralow AMH levels compared with age-matched normal AMH cycles demonstrated more than a fivefold greater preretrieval cancellation rate and a more than twofold less live-birth rate per cycle.

Refusing treatment solely on the basis of ultralow AMH levels is not advisable, but patients should be counseled appropriately about the prognostic factors for cancellation and outcomes.

  • Daniel J. Kaser, MD

    Dear Dr. Seifer and colleagues,
    Thanks for this important contribution regarding ART outcomes among women with ultralow (<0.17ng/mL) AMH values, which proves to be quite helpful for patient counseling. Are data available from SART CORS regarding the type of stimulation protocol prescribed (e.g., micro flare vs. estradiol patch priming etc) for patients with AMH and the likelihood of cycle cancellation, etc?
    Thanks very much for your comments.

Translate »